FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Barry Kahan

Research Profile

Procedures

Chemicals & Drugs

Physiology

Living Beings

Anatomy

Kidneys

Co-author Network

Publications

TOP 3
Barry D Kahan
Transplantation proceedings--a decade of evolution.
Barry D Kahan
Fifty years in the vineyard of transplantation: looking back.
E Gyurus; Z Kaposztas; Barry D Kahan
Sirolimus therapy predisposes to new-onset diabetes mellitus after renal transplantation: a long-term analysis of various treatment regimens.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Barry Kahan (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Barry D Kahan
Transplantation proceedings--a decade of evolution.
Transplantation proceedings 2012;44(1):3-5.
2011: Barry D Kahan
Fifty years in the vineyard of transplantation: looking back.
Transplantation proceedings 2011;43(8):2853-9.
2011: E Gyurus; Z Kaposztas; Barry D Kahan
Sirolimus therapy predisposes to new-onset diabetes mellitus after renal transplantation: a long-term analysis of various treatment regimens.
Transplantation proceedings 2011;43(5):1583-92.
2011: Barry D Kahan
Frontiers in immunosuppression.
Transplantation proceedings 2011;43(3):822-5.
2011: Barry D Kahan
Forty years of publication of Transplantation Proceedings--the fourth decade: Globalization of the enterprise.
Transplantation proceedings 2011;43(1):3-29.
2010: Barry D Kahan; Carlos Benavides; Linda Schoenberg; Jeannette Podbielski; C Green
Addition of induction therapy offsets the hazard of marked calcineurin minimization among renal transplant recipients treated with sirolimus.
Clinical nephrology 2010;73(5):344-53.
2010: Richard J Knight; Hemangshu Podder; Ronald H Kerman; Amy Lawless; Stephen M Katz; Charles T Van Buren; A Osama Gaber; Barry D Kahan
Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation.
Transplantation 2010;89(6):727-32.
2010: Virgilio G Petero; Zsolt Kaposztas; Barry D Kahan
Repeat renal allografts treated with sirolimus, cyclosporine, anti-thymocyte globulin induction and continuous steroids achieve similar immunosuppressive efficacy as primary transplants.
Clinical transplantation 2010;24(2):243-51.
2009: Ida Fernandes; Ye Zhang; Yuhua Qi; Mou-Er Wang; Hemangshu Podder; Wojciech Lisik; Richard Knight; Barry D Kahan; Stanislaw M Stepkowski
Impact of reduced nephron mass on cyclosporine- and/or sirolimus-induced nephrotoxicity.
Transplantation 2009;88(12):1323-31.
2009: Z Kaposztas; Barry D Kahan; Stephen M Katz; Charles T Van Buren; L Cherem
Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report.
Transplantation proceedings 2009;41(10):4407-10.
2009: Barry D Kahan
Forty years of publication of transplantation proceedings-the third decade: the expansion of the enterprise.
Transplantation proceedings 2009;41(10):3975-4020.
2009: Barry D Kahan
Current approaches to the use of sirolimus in renal transplantation.
Transplantation proceedings 2009;41(8):3011-5.
2009: Barry D Kahan
Forty years of publication of transplantation proceedings--the second decade: the cyclosporine revolution.
Transplantation proceedings 2009;41(5):1423-37.
2009: A Taylor; Barry D Kahan
Living donor kidney transplantation without transmission of multiple sclerosis after 10 years.
Clinical nephrology 2009;71(4):454-5.
2009: Barry D Kahan
The ruby anniversary: forty years of publication of Transplantation Proceedings - the first decade: the flowering of immunology and immunogenetics.
Transplantation proceedings 2009;41(1):5-10.
2009: Z Kaposztas; Hemangshu Podder; Shamila Mauiyyedi; Orieji C Illoh; Ronald H Kerman; M Reyes; V Pollard; Barry D Kahan
Impact of rituximab therapy for treatment of acute humoral rejection.
Clinical transplantation 2009;23(1):63-73.
2008: Barry D Kahan
Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine.
Transplantation proceedings 2008;40(10 Suppl):S17-20.
2008: A Osama Gaber; Barry D Kahan; Charles Van Buren; Seth L Schulman; Joseph Scarola; John F Neylan
Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Transplantation 2008;86(9):1187-95.
2008: Richard J Knight; Ronald H Kerman; E McKissick; A Lawless; Hemangshu Podder; Stephen Katz; Charles T Van Buren; Barry D Kahan
Selective corticosteroid and calcineurin-inhibitor withdrawal after pancreas-kidney transplantation utilizing thymoglobulin induction and sirolimus maintenance therapy.
Clinical transplantation 2008;22(5):645-50.
2008: Z Kaposztas; W B Etheridge; Barry D Kahan
Case report: successful treatment of posttransplant lymphoproliferative disorder and quiescence of dermatomyositis with rituximab and sirolimus.
Transplantation proceedings 2008;40(5):1744-6.
2008: Barry D Kahan; Jeannette Podbielski; B Childs
The impact of conversion from mycophenolate mofetil to mycophenolate sodium among renal transplant recipients on a sirolimus-based regimen.
Transplantation proceedings 2008;40(5):1429-34.
2008: James T Burke; Yves Brault; Barry D Kahan; Donald E Hricik; Josep M Grinyó; Jeremy R Chapman; Martin Polinsky; John F Neylan
Accuracy and variability of equations to estimate glomerular filtration rates in renal transplant patients receiving sirolimus and/or calcineurin inhibitor immunosuppression.
Transplant international : official journal of the European Society for Organ Transplantation 2008;21(5):434-40.
2008: Barry D Kahan
Frontiers in immunosuppression.
Transplantation proceedings 2008;40(1):11-5.
2007: Wojciech Lisik; Linda Schoenberg; Robert E Lasky; Barry D Kahan
Statins benefit outcomes of renal transplant recipients on a sirolimus-cyclosporine regimen.
Transplantation proceedings 2007;39(10):3086-92.
2007: Róbert Langer; András Tóth; Zsolt Máthé; Ádám Remport; Jenő Járay; Barry D Kahan
[Lymphocele and kidney transplantation].
Orvosi hetilap 2007;148(31):1475-80.
2007: Carlos Benavides; Vida B Pollard; Shamila Mauiyyedi; Hemangshu Podder; Richard Knight; Barry D Kahan
BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes.
Transplantation 2007;84(1):83-8.
2007: Richard J Knight; Martin Villa; Robert Laskey; Carlos Benavides; Linda Schoenberg; Maria Welsh; Ronald H Kerman; Hemangshu Podder; Charles T Van Buren; Stephen M Katz; Barry D Kahan
Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients.
Clinical transplantation 2007;21(4):460-5.
2007: Katsuhiro Kobayashi; Michael L Censullo; Lucho L Rossman; Polina N Kyriakides; Barry D Kahan; Alan M Cohen
Interventional radiologic management of renal transplant dysfunction: indications, limitations, and technical considerations.
Radiographics : a review publication of the Radiological Society of North America, Inc 2007;27(4):1109-30.
2007: Barry D Kahan
Losing the kingdom: the case against commercial organ donation.
Nature clinical practice. Urology 2007;4(6):290-1.
2006: Barry D Kahan; Jeannette Podbielski; Linda Schoenberg
Use of sirolimus to facilitate steroid withdrawal from a cyclosporine regimen.
Transplantation proceedings 2006;38(9):2842-6.
2006: Richard J Knight; Barry D Kahan
The place of sirolimus in kidney transplantation: can we reduce calcineurin inhibitor renal toxicity?
Kidney international 2006;70(6):994-9.
2006: Carlos Benavides; Zsolt Csapó; K Timmins; L Holley; Stephen M Katz; Charles T Van Buren; Barry D Kahan
Fibromuscular dysplasia recurrence after kidney transplantation: case report.
Clinical nephrology 2006;66(1):67-70.
2006: Zsolt Csapó; Richard J Knight; Hemangshu Podder; Ronald H Kerman; Linda Schoenberg; Stephen M Katz; Charles T Van Buren; Barry D Kahan
Long-term outcomes of single paediatric vs. ideal adult renal allograft transplants in adult recipients.
Clinical transplantation 2006;20(4):423-6.
2006: Richard J Knight; Ronald H Kerman; Scott Zela; Jeannette Podbielski; Hemangshu Podder; Charles T Van Buren; Stephen Katz; Barry D Kahan
Pancreas transplantation utilizing thymoglobulin, sirolimus, and cyclosporine.
Transplantation 2006;81(8):1101-5.
2006: Yarkin Yakupoglu; J F Buell; S Woodle; Barry D Kahan
Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy.
Transplantation proceedings 2006;38(2):358-61.
2006: Barry D Kahan; Herman Podder
Anesthetic rejection followed by surgical salvage.
Clinical transplants 2006;():572-3.
2006: Herman Podder; Ronald H Kerman; Orieji C Illoh; Barry D Kahan
Sickle cell disease: a formidable enemy of the transplanter.
Clinical transplants 2006;():570-1.
2006: Wojciech Lisik; Barry D Kahan
Individualization of immunosuppressive therapy. II. Sirolimus as a less nephrotoxic alternative to calcineurin inhibitors.
Transplantation proceedings 2006;38(1):69-73.
2006: Ye Zhang; Robert A Kirken; Lucrezia Furian; Slawa Janczewska; Xuimei Qu; Wayne W Hancock; Mouer Wang; Neelam Tejpal; Ronald H Kerman; Barry D Kahan; Stanislaw M Stepkowski
Allograft rejection requires STAT5a/b-regulated antiapoptotic activity in T cells but not B cells.
Journal of immunology (Baltimore, Md. : 1950) 2006;176(1):128-37.
2005: M E Hong; JC Hong; Stanislaw M Stepkowski; Barry D Kahan
Correlation between cyclosporine-induced nephrotoxicity in reduced nephron mass and expression of kidney injury molecule-1 and aquaporin-2 gene.
Transplantation proceedings 2005;37(10):4254-8.
2005: Hemangshu Podder; Barry D Kahan
Individualization of immunosuppressive therapy: I. Sirolimus improves outcomes in African-American renal transplant recipients.
Transplantation proceedings 2005;37(9):3723-6.
2005: Richard J Knight; Ronald H Kerman; E McKissick; A Lawless; Hemangshu Podder; Stephen Katz; Charles T Van Buren; Barry D Kahan
A pilot study of immunosuppression minimization after pancreas-kidney transplantation utilizing thymoglobulin induction and sirolimus maintenance therapy.
Transplantation proceedings 2005;37(8):3538-41.
2005: Stanislaw M Stepkowski; Judy Kao; Mou-Er Wang; Neelam Tejpal; Hemangshu Podder; Lucrezia Furian; Jonathan R Dimmock; Amitabh Jha; Umashankar Das; Barry D Kahan; Robert A Kirken
The Mannich base NC1153 promotes long-term allograft survival and spares the recipient from multiple toxicities.
Journal of immunology (Baltimore, Md. : 1950) 2005;175(7):4236-46.
2005: Barry D Kahan; Yarkin Yakupoglu; Linda Schoenberg; Richard J Knight; Stephen M Katz; Deijan Lai; Charles T Van Buren
Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients.
Transplantation 2005;80(6):749-58.
2005: Zsolt Csapó; Carlos Benavides; Hemangshu Podder; V Pollard; Barry D Kahan
Campath-1H as rescue therapy for the treatment of acute rejection in kidney transplant patients.
Transplantation proceedings 2005;37(5):2032-6.
2005: Richard J Knight; Ronald H Kerman; Hemangshu Podder; Stephen M Katz; Charles T Van Buren; Barry D Kahan
Graft survival and immune regulation of pancreas allograft recipients induced with thymoglobulin, sirolimus, and cyclosporine.
Transplantation proceedings 2005;37(2):1280-2.
2005: Carlos Benavides; K H Mahmoud; Richard Knight; C Barcenas; Barry D Kahan; Charles T Van Buren
Rabbit antithymocyte globulin: a postoperative risk factor for sirolimus-treated renal transplant patients?
Transplantation proceedings 2005;37(2):822-6.
2005: Zsolt Csapó; Richard J Knight; Hemangshu Podder; Ronald H Kerman; Linda Schoenberg; Stephen M Katz; Charles T Van Buren; Barry D Kahan
Transplantation of single pediatric kidneys into adult recipients.
Transplantation proceedings 2005;37(2):697-8.
2004: Hemangshu Podder; Barry D Kahan
Janus kinase 3: a novel target for selective transplant immunosupression.
Expert opinion on therapeutic targets 2004;8(6):613-29.
2004: Barry D Kahan
Sirolimus-based immunosuppression: present state of the art.
Journal of nephrology 2004;17 Suppl 8():S32-9.
2004: Róbert Langer; Mouer Wang; Stanislaw M Stepkowski; Wayne W Hancock; Rongxiang Han; Ping Li; Lily Feng; Robert A Kirken; Kurt L Berens; Brian Dupre; Hemangshu Podder; Richard A F Dixon; Barry D Kahan
Selectin inhibitor bimosiamose prolongs survival of kidney allografts by reduction in intragraft production of cytokines and chemokines.
Journal of the American Society of Nephrology : JASN 2004;15(11):2893-901.
2004: Richard J Knight; Ronald H Kerman; Linda Schoenberg; Hemangshu Podder; Charles T Van Buren; Stephen Katz; Barry D Kahan
The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function.
Transplantation 2004;78(6):904-10.
2004: Barry D Kahan; Stanislaw M Stepkowski; Murat Kilic; Stephen M Katz; Charles T Van Buren; Maria S Welsh; Joseph A Tami; William R Shanahan
Phase I and phase II safety and efficacy trial of intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) for the prevention of acute allograft rejection.
Transplantation 2004;78(6):858-63.
2004: Richard J Knight; Scott Zela; Linda Schoenberg; Hemangshu Podder; Ronald H Kerman; Stephen Katz; Charles T Van Buren; Barry D Kahan
The effect of pancreas transplantation on peripheral vascular disease complications.
Transplantation proceedings 2004;36(4):1069-71.
2004: Barry D Kahan
FTY720: from bench to bedside.
Transplantation proceedings 2004;36(2 Suppl):531S-543S.
2004: Barry D Kahan
Therapeutic drug monitoring of cyclosporine: 20 years of progress.
Transplantation proceedings 2004;36(2 Suppl):378S-391S.
2004: Barry D Kahan
Sirolimus: a ten-year perspective.
Transplantation proceedings 2004;36(1):71-5.
2003: John Perez; Stanislaw M Stepkowski; Ping Song; Barton W Trawick; Mou-Er Wang; Slawa Janczewska; Barry D Kahan
Selection of lowly immunogenic and highly tolerogenic donor and recipient allochimeric class I major histocompatibility complex proteins.
Transplantation 2003;76(8):1201-7.
2003: Barry D Kahan; Janet L Karlix; Ronald M Ferguson; Alan B Leichtman; Shamkant Mulgaonkar; Thomas A Gonwa; Andrej Skerjanec; Robert Schmouder; Lawrence Chodoff
Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study.
Transplantation 2003;76(7):1079-84.
2003: Barry D Kahan
Individuality: the barrier to optimal immunosuppression.
Nature reviews. Immunology 2003;3(10):831-8.
2003: Barry D Kahan
The emerging matrix of immunosuppressive agents.
Transplantation proceedings 2003;35(6):2365-8.
2003: Barry D Kahan; Robert A Kirken; Stanislaw M Stepkowski
New approaches to transplant immunosuppression.
Transplantation proceedings 2003;35(5):1621-3.
2003: Shih-Chieh Chueh; Barry D Kahan
Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis.
Transplantation 2003;76(2):375-82.
2003: Fazil Tuncay Aki; Barry D Kahan
FTY720: A new kid on the block for transplant immunosuppression.
Expert opinion on biological therapy 2003;3(4):665-81.
2003: Yarkin Yakupoglu; Barry D Kahan
Sirolimus: a current perspective.
Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 2003;1(1):8-18.
2003: Barry D Kahan
Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation.
Transplantation proceedings 2003;35(3 Suppl):37S-51S.
2003: Barry D Kahan; Richard Knight; Linda Schoenberg; J Pobielski; Ronald H Kerman; K Mahalati; Yarkin Yakupoglu; Fazil Tuncay Aki; Stephen Katz; Charles T Van Buren
Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience.
Transplantation proceedings 2003;35(3 Suppl):25S-34S.
2003: Richard J Knight; Ronald H Kerman; Scott Zela; Hemangshu Podder; Charles T Van Buren; Stephen Katz; Barry D Kahan
Thymoglobulin, sirolimus, and reduced-dose cyclosporine provides excellent rejection prophylaxis for pancreas transplantation.
Transplantation 2003;75(8):1301-6.
2002: Barry D Kahan
Sirolimus and FTY720: new approaches to transplant immunosuppression.
Transplantation proceedings 2002;34(7):2520-2.
2002: Róbert Langer; Barry D Kahan
Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients.
Transplantation 2002;74(6):804-8.
2002: Róbert Langer; Barry D Kahan
Alexis Carrel's legacy: visionary of vascular surgery and organ transplantation.
Transplantation proceedings 2002;34(4):1061-6.
2002: Stanislaw M Stepkowski; Robert A Kirken; Barton W Trawick; Min Wang; Neelam Tejpal; Mou-Er Wang; Ling Tian; James Clark; Barry D Kahan
Allochimeric class I MHC protein-induced tolerance by partial TCR engagement requires activation of both CTL4- and common gamma-chain-dependent cytokine signals.
Transplantation 2002;73(8):1227-35.
2002: John M Kovarik; Bruce Kaplan; Helio Tedesco Silva; Barry D Kahan; Jacques Dantal; Stefan Vitko; Robert Boger; Christiane Rordorf
Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range.
Transplantation 2002;73(6):920-5.
2002: Róbert Langer; Charles T Van Buren; Stephen M Katz; Barry D Kahan
De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine-sirolimus combination.
Transplantation 2002;73(5):756-60.
2002: Róbert Langer; Barry D Kahan
100 years ago: Ullmann's pioneering operation--autotransplantation of the kidney.
Transplantation proceedings 2002;34(2):429-33.
2002: Barry D Kahan; Paul Keown; Gary A Levy; Atholl Johnston
Therapeutic drug monitoring of immunosuppressant drugs in clinical practice.
Clinical therapeutics 2002;24(3):330-50; discussion 329.
2002: Barry D Kahan
The limitations of calcineurin and mTOR inhibitors: new directions for immunosuppressive strategies.
Transplantation proceedings 2002;34(1):130-3.
2002: Barry D Kahan
Update on pharmacokinetic/pharmacodynamic studies with FTY720 and sirolimus.
Therapeutic drug monitoring 2002;24(1):47-52.
2002: Stanislaw M Stepkowski; Rebecca A Erwin-Cohen; Fariba Behbod; Mou-Er Wang; Xuimei Qu; Neelam Tejpal; Zsuzsanna S Nagy; Barry D Kahan; Robert A Kirken
Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin.
Blood 2002;99(2):680-9.
2001: Barry D Kahan
Sirolimus: a comprehensive review.
Expert opinion on pharmacotherapy 2001;2(11):1903-17.
2001: Stanislaw M Stepkowski; Robert A Kirken; Zsuzsanna S Nagy; Barton W Trawick; Min Wang; Neelam Tejpal; Mou-Er Wang; Ling Tian; James Clark; Barry D Kahan
The role of Stat5 in the induction of regulatory T cells in transplantation tolerance.
Transplantation proceedings 2001;33(7-8):3835-6.
2001: Stanislaw M Stepkowski; Zsuzsanna S Nagy; Barry D Kahan; Robert A Kirken
The role of signals 1, 2, and 3 in induction of transplantation tolerance.
Transplantation proceedings 2001;33(7-8):3831-2.
2001: Stanislaw M Stepkowski; Wenhau Chen; C Frank Bennett; Tom Condon; Kim Stecker; Ling Tian; Barry D Kahan
Phosphorothioate/methoxyethyl-modified ICAM-1 antisense oligonucleotides improves prevention of ischemic/reperfusion injury.
Transplantation proceedings 2001;33(7-8):3705-6.
2001: Stanislaw M Stepkowski; Zsuzsanna S Nagy; Mou-Er Wang; Fariba Behbod; Rebecca A Erwin-Cohen; Barry D Kahan; Robert A Kirken
PNU156804 inhibits Jak3 tyrosine kinase and rat heart allograft rejection.
Transplantation proceedings 2001;33(7-8):3272-3.
2001: Róbert Langer; Charles T Van Buren; Stephen M Katz; Barry D Kahan
De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine a sirolimus combination.
Transplantation proceedings 2001;33(7-8):3236-7.
2001: K Mahalati; Barry D Kahan
A pilot study of steroid withdrawal from kidney transplant recipients on sirolimus-cyclosporine a combination therapy.
Transplantation proceedings 2001;33(7-8):3232-3.
2001: Barry D Kahan
The evolution of therapeutic drug monitoring of cyclosporine.
Transplantation proceedings 2001;33(7-8):3086-8.
2001: Barry D Kahan
FTY720: a new dimension in transplantation.
Transplantation proceedings 2001;33(7-8):3081-3.
2001: Barry D Kahan
The matrix of clinical immunosuppression for transplantation.
Transplantation proceedings 2001;33(7-8):3035-7.
2001: Barry D Kahan; J S Camardo
Rapamycin: clinical results and future opportunities.
Transplantation 2001;72(7):1181-93.
2001: Barry D Kahan; Stephen M Koch
Current immunosuppressant regimens: considerations for critical care.
Current opinion in critical care 2001;7(4):242-50.
2001: Barry D Kahan; W G Kramer
Median effect analysis of efficacy versus adverse effects of immunosuppressants.
Clinical pharmacology and therapeutics 2001;70(1):74-81.
2001: Barry D Kahan
Potential therapeutic interventions to avoid or treat chronic allograft dysfunction.
Transplantation 2001;71(11 Suppl):SS52-7.
2001: JC Hong; Barry D Kahan
Sirolimus rescue therapy for refractory rejection in renal transplantation.
Transplantation 2001;71(11):1579-84.
2001: Hemangshu Podder; Jeannette Podbielski; I Hussein; Stephen Katz; Charles T Van Buren; Barry D Kahan
Sirolimus improves the two-year outcome of renal allografts in African-American patients.
Transplant international : official journal of the European Society for Organ Transplantation 2001;14(3):135-42.
2001: Barry D Kahan; Bruce Kaplan; M I Lorber; M Winkler; N Cambon; Robert Boger
RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection.
Transplantation 2001;71(10):1400-6.
2001: JC Hong; Barry D Kahan
A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft function.
Transplantation 2001;71(9):1320-8.
2001: Hemangshu Podder; Stanislaw M Stepkowski; Kimberly L Napoli; James Clark; Regina Verani; T C Chou; Barry D Kahan
Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations.
Journal of the American Society of Nephrology : JASN 2001;12(5):1059-71.
2001: Fariba Behbod; Rebecca A Erwin-Cohen; Mou-Er Wang; Barton W Trawick; Xuimei Qu; Regina Verani; Barry D Kahan; Stanislaw M Stepkowski; Robert A Kirken
Concomitant inhibition of Janus kinase 3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat heart allografts.
Journal of immunology (Baltimore, Md. : 1950) 2001;166(6):3724-32.
2001: Barry D Kahan; Kimberly L Napoli; Jeannette Podbielski; I Hussein; SH Katz; Charles T Van Buren
Therapeutic drug monitoring of sirolimus for optimal renal transplant outcomes.
Transplantation proceedings 2001;33(1-2):1278.
2001: JC Hong; Barry D Kahan
A calcineurin antagonist-free induction immunosuppression strategy for delayed graft function in renal transplantation.
Transplantation proceedings 2001;33(1-2):1271-2.
2001: K Mahalati; Barry D Kahan
Sirolimus permits steroid withdrawal from a cyclosporine regimen.
Transplantation proceedings 2001;33(1-2):1270.
2001: Hemangshu Podder; Jeannette Podbielski; I Hussein; Stephen M Katz; Charles T Van Buren; Barry D Kahan
Impact of sirolimus on renal transplant outcomes in African Americans.
Transplantation proceedings 2001;33(1-2):1226.
2001: Hemangshu Podder; Stanislaw M Stepkowski; Kimberly L Napoli; Barry D Kahan
Pharmacokinetic interactions between sirolimus and cyclosporine exacerbate renal dysfunction.
Transplantation proceedings 2001;33(1-2):1086.
2001: JC Hong; Barry D Kahan
Sirolimus rescue therapy for refractory rejection in renal transplant recipients.
Transplantation proceedings 2001;33(1-2):1033.
2001: Wenhau Chen; C Frank Bennett; Tom Condon; Kim Stecker; Ling Tian; Barry D Kahan; Stanislaw M Stepkowski
Methoxyethyl modification of phosphorothioate ICAM-1 antisense oligonucleotides improves prevention of ischemic/reperfusion injury.
Transplantation proceedings 2001;33(1-2):854.
2001: Howard M. Gebel; Robert A. Bray; JA Ruth; Gazi B Zibari; John C McDonald; Barry D Kahan; R H Kerman
Flow PRA to detect clinically relevant HLA antibodies.
Transplantation proceedings 2001;33(1-2):477.
2001: Ronald H Kerman; Stephen M Katz; Charles T Van Buren; JA Ruth; E McKissick; S Rasmussen; Barry D Kahan
Posttransplant immune monitoring of anti-HLA antibody.
Transplantation proceedings 2001;33(1-2):402.
2001: Ronald H Kerman; Stephen M Katz; Charles T Van Buren; C Garcia; Barry D Kahan
Addition of rapamycin to cyclosporine-prednisone based immunosuppression reduces the clinical risk of pretransplant anti-HLA antibody.
Transplantation proceedings 2001;33(1-2):401.
2001: M Wang; Robert A Kirken; Fariba Behbod; Rebecca A Erwin-Cohen; Stanislaw M Stepkowski; Barry D Kahan
Inhibition of Jak3 tyrosine kinase by PNU156804 blocks rat heart allograft rejection.
Transplantation proceedings 2001;33(1-2):201.
2001: Stanislaw M Stepkowski; Robert A Kirken; M Wang; J Yu; K Akioka; Barry D Kahan
Tolerance induction by alteration of T cell receptor (TCR) signaling using an allochimeric donor/recipient class I MHC protein.
Transplantation proceedings 2001;33(1-2):131.
2001: Robert A Kirken; Rebecca A Erwin-Cohen; Fariba Behbod; M Wang; Stanislaw M Stepkowski; Barry D Kahan
Tyrphostin AG490 selectively inhibits activation of the JAK3/STAT5/MAPK pathway and rejection of rat heart allografts.
Transplantation proceedings 2001;33(1-2):95.
2001: K Mahalati; Barry D Kahan
Clinical pharmacokinetics of sirolimus.
Clinical pharmacokinetics 2001;40(8):573-85.
2001: John M Kovarik; Barry D Kahan; Bruce Kaplan; M Lorber; M Winkler; Marisel Rouilly; Christophe Gerbeau; N Cambon; Robert Boger; Christiane Rordorf
Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
Clinical pharmacology and therapeutics 2001;69(1):48-56.
2000: Stephen M Katz; FC Bennett; Kim Stecker; J H Clark; T Pham; Mou-Er Wang; Barry D Kahan; Stanislaw M Stepkowski
ICAM-1 antisense oligodeoxynucleotide improves islet allograft survival and function.
Cell transplantation 2000;9(6):817-28.
2000: Herwig-Ulf Meier-Kriesche; Rita D Swinford; Barry D Kahan; P Brannan; Ronald J Portman
Reduced variability of neoral pharmacokinetic studies in pediatric renal transplantation.
Pediatric nephrology (Berlin, Germany) 2000;15(1-2):2-6.
2000: M Okamoto; Stanislaw M Stepkowski; Min Wang; Barry D Kahan
Use of allochimeric proteins to mitigate graft-versus-host and host-versus-graft immune responses to rat small bowel allografts.
Transplantation 2000;70(7):1060-7.
2000: Barry D Kahan
Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group.
Lancet 2000;356(9225):194-202.
2000: Barry D Kahan; Maria Welsh; D L Urbauer; M B Mosheim; Kathleen M Beusterien; M R Wood; Linda Schoenberg; J Dicesare; Stephen M Katz; Charles T Van Buren
Low intraindividual variability of cyclosporin A exposure reduces chronic rejection incidence and health care costs.
Journal of the American Society of Nephrology : JASN 2000;11(6):1122-31.
2000: JC Hong; Barry D Kahan
Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management.
Transplantation 2000;69(10):2085-90.
2000: Stephen M Katz; JC Hong; Barry D Kahan
New immunosuppressive agents.
Transplantation proceedings 2000;32(3):620-1.
2000: Barry D Kahan; Kimberly L Napoli; PA Kelly; Jeannette Podbielski; I Hussein; D L Urbauer; SH Katz; Charles T Van Buren
Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity.
Clinical transplantation 2000;14(2):97-109.
2000: JC Hong; Barry D Kahan
Immunosuppressive agents in organ transplantation: past, present, and future.
Seminars in nephrology 2000;20(2):108-25.
2000: K Yuzawa; S M Stephkowski; Min Wang; Barry D Kahan
FTY720 blocks allograft rejection by homing of lymphocytes in vivo.
Transplantation proceedings 2000;32(2):269.
2000: Barry D Kahan; Stanislaw M Stepkowski; Kimberly L Napoli; Stephen M Katz; Richard J Knight; Charles T Van Buren
The development of sirolimus: The University of Texas-Houston experience.
Clinical transplants 2000;():145-58.
2000: K Mahalati; Barry D Kahan
Pharmacological surrogates of allograft outcome.
Annals of transplantation : quarterly of the Polish Transplantation Society 2000;5(2):14-23.
1999: Ronald H Kerman; Brian Susskind; I Buyse; P Pryzbylowski; JA Ruth; S Warnell; Scott A Gruber; Stephen Katz; Charles T Van Buren; Barry D Kahan
Flow cytometry-detected IgG is not a contraindication to renal transplantation: IgM may be beneficial to outcome.
Transplantation 1999;68(12):1855-8.
1999: Barry D Kahan; B A Julian; M D Pescovitz; Y Vanrenterghem; J Neylan
Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group.
Transplantation 1999;68(10):1526-32.
1999: John M Kovarik; Barry D Kahan; P. R. Rajagopalan; W Bennett; Laura L Mulloy; Christophe Gerbeau; ML Hall
Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group.
Transplantation 1999;68(9):1288-94.
1999: Herwig-Ulf Meier-Kriesche; M A Bonilla-Felix; Maria E Ferris; Rita D Swinford; Barry D Kahan; P Brannan; Ronald J Portman
A limited sampling strategy for the estimation of Neoral AUCs in pediatric patients.
Pediatric nephrology (Berlin, Germany) 1999;13(9):742-7.
1999: K Akioka; R Kirkin; Min Wang; Ling Tian; J Yu; Stanislaw M Stepkowski; Barry D Kahan
Reduced expression of NF-AT and NF-kappa B transcription factors in tolerant recipients treated with tolerogenic allochimeric donor/recipient class I MHC protein.
Transplantation proceedings 1999;31(7):2745-6.
1999: Barry D Kahan; R L Wong; C Carter; SH Katz; J Von Fellenberg; Charles T Van Buren; S Appel-Dingemanse
A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients.
Transplantation 1999;68(8):1100-6.
1999: Wenhau Chen; C Frank Bennett; Mou-Er Wang; D Dragun; Ling Tian; Kim Stecker; J H Clark; Barry D Kahan; Stanislaw M Stepkowski
Perfusion of kidneys with unformulated "naked" intercellular adhesion molecule-1 antisense oligodeoxynucleotides prevents ischemic/reperfusion injury.
Transplantation 1999;68(6):880-7.
1999: JC Hong; Barry D Kahan
Use of anti-CD25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression.
Transplantation 1999;68(5):701-4.
1999: Barry D Kahan
The potential role of rapamycin in pediatric transplantation as observed from adult studies.
Pediatric transplantation 1999;3(3):175-80.
1999: K B Stroehlein; J R Stroehlein; Barry D Kahan; Scott A Gruber
Gastric mucosal calcinosis in renal transplant patients.
Transplantation proceedings 1999;31(5):2124-6.
1999: Barry D Kahan
An immunosuppressive triumvirate to minimize renal injuries associated with calcineurin antagonist therapy.
Transplantation 1999;68(1):12-4.
1999: Ling Tian; Min Wang; J Yu; Barry D Kahan; Stanislaw M Stepkowski
Nucleotide sequences of three distinct complementary DNA clones encoding rat class II major histocompatibility complex RT1.D beta-chain proteins.
Immunogenetics 1999;49(7-8):735-7.
1999: Barry D Kahan
Considerations concerning generic formulations of immunosuppressive drugs.
Transplantation proceedings 1999;31(3):1635-41.
1999: Barry D Kahan
Recommendations concerning the introduction of generic formulations of cyclosporine.
Transplantation proceedings 1999;31(3):1634; discussion 1675-84.
1999: J Perez; J Yu; Stanislaw M Stepkowski; Barry D Kahan
Immunization with Escherichia coli-produced soluble MHC class I proteins induces accelerated rejection or prolonged survival of rat cardiac allografts.
Transplantation proceedings 1999;31(3):1560.
1999: Stanislaw M Stepkowski; J Yu; Min Wang; Barry D Kahan
Induction of tolerance by oral administration of a tolerogenic allochimeric donor/recipient class I MHC protein.
Transplantation proceedings 1999;31(3):1557.
1999: Min Wang; J Yu; Stanislaw M Stepkowski; Barry D Kahan
Localization of immunogenic and tolerogenic epitopes in the RT1.A1 alloantigen.
Transplantation proceedings 1999;31(3):1517-8.
1999: James Clark; Ronald H Kerman; Brian Susskind; Stephen Katz; Charles T Van Buren; Barry D Kahan
Correlation of pretransplant allosensitization with severity of rejection biopsy.
Transplantation proceedings 1999;31(1-2):751-2.
1999: Barry D Kahan
Cyclosporine: a revolution in transplantation.
Transplantation proceedings 1999;31(1-2A):14S-15S.
1999: Bruce Kaplan; Herwig-Ulf Meier-Kriesche; Kimberly L Napoli; Barry D Kahan
Correlation between pretransplantation test dose cyclosporine pharmacokinetic profiles and posttransplantation sirolimus blood levels in renal transplant recipients.
Therapeutic drug monitoring 1999;21(1):44-9.
1999: Barry D Kahan; P. R. Rajagopalan; M Hall
Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group.
Transplantation 1999;67(2):276-84.
1999: P Przybylowski; M Balogna; Branislav Radovancevic; O Howard Frazier; Brian Susskind; Charles T Van Buren; Stephen Katz; Barry D Kahan; Ronald H Kerman
The role of flow cytometry-detected IgG and IgM anti-donor antibodies in cardiac allograft recipients.
Transplantation 1999;67(2):258-62.
1999: P Troncoso; Stanislaw M Stepkowski; Mou-Er Wang; Xuimei Qu; Shih-Chieh Chueh; James Clark; Barry D Kahan
Prophylaxis of acute renal allograft rejection using FTY720 in combination with subtherapeutic doses of cyclosporine.
Transplantation 1999;67(1):145-51.
1998: Ronald H Kerman; Brian Susskind; JA Ruth; Stephen Katz; Charles T Van Buren; Barry D Kahan
Can an immunologically, nonreactive potential allograft recipient undergo transplantation without a donor-specific crossmatch?
Transplantation 1998;66(12):1833-4.
1998: Brian Susskind; Ronald H Kerman; R Nelson; J Gregory; T La; A Bayat; M Dang; Charles T Van Buren; Stephen Katz; Barry D Kahan
Comparison between enzyme-linked immunosorbent assay and cytotoxic cross-match procedures for detecting IgG anti-donor antibodies.
Transplantation 1998;66(12):1823-6.
1998: Barry D Kahan; Jeannette Podbielski; Kimberly L Napoli; Stephen M Katz; Herwig-Ulf Meier-Kriesche; Charles T Van Buren
Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation.
Transplantation 1998;66(8):1040-6.
1998: Stanislaw M Stepkowski; Mou-Er Wang; Tom Condon; S Cheng-Flournoy; Kim Stecker; M Graham; Xuimei Qu; Ling Tian; Wenhau Chen; Barry D Kahan; C Frank Bennett
Protection against allograft rejection with intercellular adhesion molecule-1 antisense oligodeoxynucleotides.
Transplantation 1998;66(6):699-707.
1998: Ronald H Kerman; Brian Susskind; David Kerman; M Lam; K Gerolami; J Williams; R Kalish; M Campbell; Stephen Katz; Charles T Van Buren; H Frazier; Branislav Radovancevic; S Fife; Barry D Kahan
Comparison of PRA-STAT, sHLA-EIA, and anti-human globulin-panel reactive antibody to identify alloreactivity in pretransplantation sera of heart transplant recipients: correlation to rejection and posttransplantation coronary artery disease.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 1998;17(8):789-94.
1998: Barry D Kahan
Renaissance of immunosuppressive therapy in the new millennium.
Transplantation proceedings 1998;30(5):2493-6.
1998: Stanislaw M Stepkowski; Min Wang; Xuimei Qu; J Yu; M Okamoto; Neelam Tejpal; Barry D Kahan
Synergistic interaction of FTY720 with cyclosporine or sirolimus to prolong heart allograft survival.
Transplantation proceedings 1998;30(5):2214-6.
1998: Barry D Kahan
FTY720: a new immunosuppressive agent with novel mechanism(s) of action.
Transplantation proceedings 1998;30(5):2210-3.
1998: Barry D Kahan; Kimberly L Napoli
Role of therapeutic drug monitoring of rapamycin.
Transplantation proceedings 1998;30(5):2189-91.
1998: Barry D Kahan
Rapamycin: personal algorithms for use based on 250 treated renal allograft recipients.
Transplantation proceedings 1998;30(5):2185-8.
1998: Barry D Kahan
High variability of drug exposure: a biopharmaceutic risk factor for chronic rejection.
Transplantation proceedings 1998;30(5):1639-41.
1998: Barry D Kahan
New dimensions in transplantation--weaving the future.
Transplantation proceedings 1998;30(5):1617-8.
1998: Herwig-Ulf Meier-Kriesche; Bruce Kaplan; P Brannan; Barry D Kahan; Ronald J Portman
A limited sampling strategy for the estimation of eight-hour neoral areas under the curve in renal transplantation.
Therapeutic drug monitoring 1998;20(4):401-7.
1998: P Troncoso; Barry D Kahan
Preclinical evaluation of a new immunosuppressive agent, FTY720.
Clinical biochemistry 1998;31(5):369-73.
1998: Barry D Kahan
Emerging strategies for the clinical application of rapamycin.
Clinical biochemistry 1998;31(5):341-4.
1998: Z T Beyga; Barry D Kahan
Surgical complications of kidney transplantation.
Journal of nephrology 1998;11(3):137-45.
1998: M J Boyle; V Baghdassarian; Stanislaw M Stepkowski; L J Dumble; Barry D Kahan
Intrasplenic liver parenchymal cells in conjunction with low-dose rapamycin and cyclosporine induce a unique and specific prolongation of rat cardiac and small bowel allograft survival.
Cell transplantation 1998;7(3):247-56.
1998: Mou-Er Wang; Neelam Tejpal; Xuimei Qu; J Yu; M Okamoto; Stanislaw M Stepkowski; Barry D Kahan
Immunosuppressive effects of FTY720 alone or in combination with cyclosporine and/or sirolimus.
Transplantation 1998;65(7):899-905.
1998: Kimberly L Napoli; Mou-Er Wang; Stanislaw M Stepkowski; Barry D Kahan
Relative tissue distributions of cyclosporine and sirolimus after concomitant peroral administration to the rat: evidence for pharmacokinetic interactions.
Therapeutic drug monitoring 1998;20(2):123-33.
1998: Shih-Chieh Chueh; Barry D Kahan
Pretransplant test-dose pharmacokinetic profiles: cyclosporine microemulsion versus corn oil-based soft gel capsule formulation.
Journal of the American Society of Nephrology : JASN 1998;9(2):297-304.
1998: M F Senel; Charles T Van Buren; Maria Welsh; Barry D Kahan
Impact of early cyclosporin average blood concentration on early kidney transplant failure.
Transplant international : official journal of the European Society for Organ Transplantation 1998;11(1):46-52.
1998: Bruce Kaplan; Herwig-Ulf Meier-Kriesche; Kimberly L Napoli; Barry D Kahan
The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent.
Clinical pharmacology and therapeutics 1998;63(1):48-53.
1997: Shih-Chieh Chueh; Ling Tian; Min Wang; Mou-Er Wang; Stanislaw M Stepkowski; Barry D Kahan
Induction of tolerance toward rat cardiac allografts by treatment with allochimeric class I MHC antigen and FTY720.
Transplantation 1997;64(10):1407-14.
1997: P A Kelly; Scott A Gruber; Fariba Behbod; Barry D Kahan
Sirolimus, a new, potent immunosuppressive agent.
Pharmacotherapy 1997;17(6):1148-56.
1997: Ling Tian; Stanislaw M Stepkowski; Xuimei Qu; Mou-Er Wang; Min Wang; J Yu; Barry D Kahan
Cytokine mRNA expression in tolerant heart allografts after immunosuppression with cyclosporine, sirolimus or brequinar.
Transplant immunology 1997;5(3):189-98.
1997: Min Wang; Stanislaw M Stepkowski; J Yu; M Wang; Barry D Kahan
Localization of cryptic tolerogenic epitopes in the alpha1-helical region of the RT1.Au alloantigen.
Transplantation 1997;63(10):1373-9.
1997: Stanislaw M Stepkowski; Min Wang; J Langowski; R Ghobrial; Xuimei Qu; J Yu; Ling Tian; Barry D Kahan
Localization of tolerogenic epitopes in the alpha 1 helical region of the rat class I major histocompatibility complex molecule.
Transplantation proceedings 1997;29(3):1663-4.
1997: Min Wang; Stanislaw M Stepkowski; Ling Tian; J Langowski; J Yu; Malgorzata Kloc; Barry D Kahan
Nucleotide sequences of rat cDNA clones coding heavy chain class I major histocompatibility complex proteins.
Transplantation proceedings 1997;29(3):1661-2.
1997: Stanislaw M Stepkowski; Ling Tian; Kimberly L Napoli; R Ghobrial; Mou-Er Wang; T C Chou; Barry D Kahan
Synergistic mechanisms by which sirolimus and cyclosporin inhibit rat heart and kidney allograft rejection.
Clinical and experimental immunology 1997;108(1):63-8.
1997: Kimberly L Napoli; Mou-Er Wang; Stanislaw M Stepkowski; Barry D Kahan
Distribution of sirolimus in rat tissue.
Clinical biochemistry 1997;30(2):135-42.
1997: Bruce Kaplan; Herwig-Ulf Meier-Kriesche; Kimberly L Napoli; Barry D Kahan
A limited sampling strategy for estimating sirolimus area-under-the-concentration curve.
Clinical chemistry 1997;43(3):539-40.
1997: Stephen M Katz; Ling Tian; Stanislaw M Stepkowski; Tammy Phan; C Frank Bennett; Barry D Kahan
Effect of ICAM-1/LFA-1 blockade on pancreatic islet allograft survival, function, and early cytokine production.
Transplantation proceedings 1997;29(1-2):748-9.
1997: Ronald H Kerman; Brian Susskind; David Kerman; M Lam; K Gerolami; J Williams; R Kalish; M Campbell; Stephen M Katz; Charles T Van Buren; Barry D Kahan
Anti-HLA antibodies detected in posttransplant renal allograft recipient sera correlate with chronic rejection.
Transplantation proceedings 1997;29(1-2):1515-6.
1997: Ronald H Kerman; Brian Susskind; J Slaton; R M Lewis; A Heydari; JA Ruth; J Williams; Charles T Van Buren; Stephen M Katz; Barry D Kahan
Improved graft survival in 100 retransplant recipients following AHG-negative crossmatching.
Transplantation proceedings 1997;29(1-2):1451-3.
1997: Ronald H Kerman; Brian Susskind; Stephen M Katz; Charles T Van Buren; Barry D Kahan
Postrenal transplant MLR hypo-responders have fewer rejections and better graft survival than MLR hyper-responders.
Transplantation proceedings 1997;29(1-2):1410-1.
1997: Stanislaw M Stepkowski; Mou-Er Wang; A Amante; D Kalinin; Xuimei Qu; T Blasdel; Tom Condon; Barry D Kahan; FC Bennett
Antisense ICAM-1 oligonucleotides block allograft rejection in rats.
Transplantation proceedings 1997;29(1-2):1285.
1997: Min Wang; J Yu; Mou-Er Wang; Ling Tian; Stanislaw M Stepkowski; Barry D Kahan
Induction of donor-specific tolerance by chimeric class I MHC molecules bearing donor alpha 1 helical amino acids.
Transplantation proceedings 1997;29(1-2):1224-5.
1997: Barry D Kahan
Sirolimus: a new agent for clinical renal transplantation.
Transplantation proceedings 1997;29(1-2):48-50.
1997: Ronald H Kerman; Stephen M Katz; Linda Schoenberg; O Baraket; Charles T Van Buren; Barry D Kahan
Ten-year follow-up of mixed lymphocyte reaction-hyporesponsive living related cyclosporine monotherapy-treated renal allograft recipients.
Transplantation proceedings 1997;29(1-2):198-9.
1997: Stanislaw M Stepkowski; Ling Tian; Mou-Er Wang; Xuimei Qu; Kimberly L Napoli; Barry D Kahan
Sirolimus in transplantation.
Archivum immunologiae et therapiae experimentalis 1997;45(5-6):383-90.
1997: Barry D Kahan
New approaches for the prevention of early graft rejection.
Kidney & blood pressure research 1997;20(3):167-9.
1997: A J Amante; Herwig-Ulf Meier-Kriesche; Linda Schoenberg; Barry D Kahan
A pharmacokinetic comparison of the corn oil versus microemulsion gelcap formulation of cyclosporin used de novo after renal transplantation.
Transplant international : official journal of the European Society for Organ Transplantation 1997;10(3):217-22.
1996: R R Ghobrial; T Hamashima; Mou-Er Wang; Min Wang; Stanislaw M Stepkowski; Barry D Kahan
Induction of transplantation tolerance by chimeric donor/recipient class I RT1.Aa molecules.
Transplantation 1996;62(7):1002-10.
1996: Stanislaw M Stepkowski; Kimberly L Napoli; Mou-Er Wang; Xuimei Qu; T C Chou; Barry D Kahan
Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats.
Transplantation 1996;62(7):986-94.
1996: G He; Min Wang; H Xu; Ling Tian; J Yu; Stanislaw M Stepkowski; Barry D Kahan
Impact of different forms of recipient antigen and different routes of antigen administration in donor pretreatment for preventing graft-versus-host disease in rat small bowel transplantation.
Transplantation proceedings 1996;28(5):2469.
1996: Barry D Kahan; M Welsh; Linda Schoenberg; L P Rutzky; Stephen M Katz; D L Urbauer; Charles T Van Buren
Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection.
Transplantation 1996;62(5):599-606.
1996: Barry D Kahan
Frontiers for the coming millennium.
Transplantation proceedings 1996;28(4):2299-306.
1996: Barry D Kahan
Case study: de novo application of Neoral in renal transplantation.
Transplantation proceedings 1996;28(4):2189-91; discussion 2192, 2195.
1996: Stephen M Katz; A Amante; Linda Schoenberg; Barry D Kahan
Oral cyclosporine preparations immediately following renal transplantation.
Transplantation proceedings 1996;28(4):2164.
1996: A J Amante; Barry D Kahan
Abbreviated AUC strategy for monitoring cyclosporine microemulsion therapy in the immediate posttransplant period.
Transplantation proceedings 1996;28(4):2162-3.
1996: Barry D Kahan
Pharmacokinetic considerations in the therapeutic application of cyclosporine in renal transplantation.
Transplantation proceedings 1996;28(4):2143-6.
1996: Ronald H Kerman; Brian Susskind; Roland Buelow; J Regan; P Pouletty; J Williams; K Gerolami; David Kerman; Stephen M Katz; Charles T Van Buren; Barry D Kahan
Correlation of ELISA-detected IgG and IgA anti-HLA antibodies in pretransplant sera with renal allograft rejection.
Transplantation 1996;62(2):201-5.
1996: M F Senel; Charles T Van Buren; S Riggs; J Clark; W B Etheridge; Barry D Kahan
Post-transplantation lymphoproliferative disorder in the renal transplant ureter.
The Journal of urology 1996;155(6):2025.
1996: J W Slaton; Barry D Kahan
Case report--sirolimus rescue therapy for refractory renal allograft rejection.
Transplantation 1996;61(6):977-9.
1996: A J Amante; Barry D Kahan
En bloc transplantation of kidneys from pediatric donors.
The Journal of urology 1996;155(3):852-6; discussion 856-7.
1996: Min Wang; Xuimei Qu; Stanislaw M Stepkowski; T C Chou; Barry D Kahan
Beneficial effect of graft perfusion with anti-T cell receptor monoclonal antibodies on survival of small bowel allografts in rat recipients treated with brequinar alone or in combination with cyclosporine and sirolimus.
Transplantation 1996;61(3):458-64.
1996: Min Wang; Stanislaw M Stepkowski; Mou-Er Wang; Ling Tian; Xuimei Qu; Y Tu; G He; Barry D Kahan
Induction of specific allograft immunity by soluble class I MHC heavy chain protein produced in a baculovirus expression system.
Transplantation 1996;61(3):448-57.
1996: Brian Susskind; Ronald H Kerman; B J Browne; B A Hartwell; B G Davis; Stephen M Katz; Charles T Van Buren; Barry D Kahan
The impact of elevated serum IgA and race on primary recipient renal allograft survival.
Transplantation 1996;61(2):205-11.
1996: Min Wang; Stanislaw M Stepkowski; J S Hebert; Ling Tian; J Yu; Barry D Kahan
Nucleotide sequences of three H-2K and three H-2D complementary DNA clones coding mouse class I MHC heavy chain proteins.
Annals of transplantation : quarterly of the Polish Transplantation Society 1996;1(3):26-31.
1996: R Ghobrial; M Karczewski; Mariano Ferraresso; Ling Tian; Stanislaw M Stepkowski; Barry D Kahan
Kinetics of in vitro immune responses of T and B cells during tolerance induction by sirolimus.
Annals of transplantation : quarterly of the Polish Transplantation Society 1996;1(4):22-9.
1996: Min Wang; Stanislaw M Stepkowski; Ling Tian; J L Langowski; J Yu; Barry D Kahan
Nucleotide sequences of three distinct clones coding for rat heavy chain class I major histocompatibility antigens.
Immunogenetics 1996;43(5):318-20.
1996: Min Wang; Stanislaw M Stepkowski; Ling Tian; J L Langowski; J S Hebert; Malgorzata Kloc; J Yu; Barry D Kahan
Nucleotide sequences of three distinct cDNA clones coding for the rat class I heavy chain RT1n antigen.
Immunogenetics 1996;45(1):73-5.
1996: M G Murgia; S Jordan; Barry D Kahan
The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients.
Kidney international 1996;49(1):209-16.
1996: M F Senel; Charles T Van Buren; W B Etheridge; C Barcenas; C Jammal; Barry D Kahan
Effects of cyclosporine, azathioprine and prednisone on Kimura's disease and focal segmental glomerulosclerosis in renal transplant patients.
Clinical nephrology 1996;45(1):18-21.
1995: T Hamashima; Stanislaw M Stepkowski; T C Chou; Barry D Kahan
Synergistic interaction of 3 M KCl-extracted donor antigens (e-HAg) with cyclosporine or cyclosporine/sirolimus for prolongation of rat heart allograft survival.
Transplant immunology 1995;3(4):335-41.
1995: Barry D Kahan; M G Murgia; J Slaton; Kimberly L Napoli
Potential applications of therapeutic drug monitoring of sirolimus immunosuppression in clinical renal transplantation.
Therapeutic drug monitoring 1995;17(6):672-5.
1995: Barry D Kahan; M Welsh; L P Rutzky
Challenges in cyclosporine therapy: the role of therapeutic monitoring by area under the curve monitoring.
Therapeutic drug monitoring 1995;17(6):621-4.
1995: Barry D Kahan
The evolution of therapeutic immunosuppression and the potential impact of drug concentration monitoring.
Therapeutic drug monitoring 1995;17(6):560-3.
1995: Stephen M Katz; B Browne; T Phan; Mou-Er Wang; C Frank Bennett; Stanislaw M Stepkowski; Barry D Kahan
Efficacy of ICAM-1 antisense oligonucleotide in pancreatic islet transplantation.
Transplantation proceedings 1995;27(6):3214.
1995: R Ghobrial; T Hamashima; Malgorzata Kloc; Laurence D Etkin; Stanislaw M Stepkowski; Barry D Kahan
Membrane-bound or soluble truncated RT1.Aa rat class I major histocompatibility antigens induce specific alloimmunity.
Transplantation 1995;60(6):602-10.
1995: R R Ghobrial; Stanislaw M Stepkowski; Barry D Kahan
Molecular engineering of the major histocompatibility complex for immunomodulation.
Clinical transplantation 1995;9(3 Pt 2):237-45.
1995: Barry D Kahan; J Dunn; C Fitts; D Van Buren; D Wombolt; R Pollak; R Carson; J W Alexander; M Choc; R Wong
Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals.
Transplantation 1995;59(4):505-11.
1995: Min Wang; Stanislaw M Stepkowski; Barry D Kahan
Donor pretreatment with anti-T-cell receptor monoclonal antibodies prevents graft-vs-host disease in brequinar-treated small bowel allograft recipients.
Transplantation proceedings 1995;27(1):383.
1995: Barry D Kahan
Concentration-controlled immunosuppressive regimens using cyclosporine with sirolimus or brequinar in human renal transplantation.
Transplantation proceedings 1995;27(1):33-6.
1995: R Ghobrial; T Hamashima; Stanislaw M Stepkowski; Barry D Kahan
Induction of transplantation tolerance by perioperative injection of "quasi-self" chimeric class I MHC antigen combined with a short cyclosporine course.
Transplantation proceedings 1995;27(1):239-40.
1995: T Hamashima; Stanislaw M Stepkowski; Barry D Kahan
Dose-dependent effect of intrathymically injected 3-mol/L KCl-extracted histocompatibility antigens to prolong heart allograft survival in rats.
Transplantation proceedings 1995;27(1):134-5.
1995: Y Tu; Stanislaw M Stepkowski; T C Chou; Barry D Kahan
The synergistic effects of cyclosporine, sirolimus, and brequinar on heart allograft survival in mice.
Transplantation 1995;59(2):177-83.
1994: Barry D Kahan
Concentration control: a key to phase I development of immunosuppressive agents.
Transplantation proceedings 1994;26(6):3203-4.
1994: Mariano Ferraresso; Ling Tian; R Ghobrial; Stanislaw M Stepkowski; Barry D Kahan
Rapamycin inhibits production of cytotoxic but not noncytotoxic antibodies and preferentially activates T helper 2 cells that mediate long-term survival of heart allografts in rats.
Journal of immunology (Baltimore, Md. : 1950) 1994;153(7):3307-18.
1994: Barry D Kahan
Role of cyclosporine: present and future.
Transplantation proceedings 1994;26(5):3082-7.
1994: T Hamashima; Stanislaw M Stepkowski; S Smith; Barry D Kahan
Synergistic effect of 3M KCl-extracted donor antigens with cyclosporine or cyclosporine/rapamycin to prolong heart allograft survival in rats.
Transplantation proceedings 1994;26(5):3053-5.
1994: Stanislaw M Stepkowski; Y Tu; T C Chou; Barry D Kahan
Synergistic interactions of cyclosporine, rapamycin, and brequinar on heart allograft survival in mice.
Transplantation proceedings 1994;26(5):3025-7.
1994: Barry D Kahan; T Chou; Neelam Tejpal; Min Wang; C Chee; Stanislaw M Stepkowski
Synergistic effects of cyclosporin analogs--A, D, G, IMM-125--with rapamycin and/or brequinar.
Transplantation proceedings 1994;26(5):3021-4.
1994: B J Browne; S Jordan; M S Welsh; Charles T Van Buren; Barry D Kahan
Diet and cyclosporin A--pharmacokinetic comparison between Neoral and Sandimmune gelatin capsules.
Transplantation proceedings 1994;26(5):2959-60.
1994: Ronald H Kerman; Pam Kimball; J Williams; A Heydari; D Cavazos; JA Ruth; Stephen Katz; Claire F Ozaki; James Clark; Barry D Kahan
Immunoregulatory mechanisms identified in liver transplant recipients.
Transplantation proceedings 1994;26(5):2857-8.
1994: R Lewis; J Podbielski; M Munsell; Stephen Katz; Charles T Van Buren; Ronald H Kerman; Barry D Kahan
Stability of renal allograft glomerular filtration rate in the cyclosporine era: 2-year follow-up.
Transplantation proceedings 1994;26(5):2619-21.
1994: Barry D Kahan
Toward quantitative theories of immunosuppressive drug action: Averroes and the Arabic and Spanish eras of medicine.
Transplantation proceedings 1994;26(5):2469-74.
1994: A J Amante; Barry D Kahan
Technical complications of renal transplantation.
The Surgical clinics of North America 1994;74(5):1117-31.
1994: B J Browne; Barry D Kahan
Renal transplantation.
The Surgical clinics of North America 1994;74(5):1097-116.
1994: Barry D Kahan; R Ghobrial
Immunosuppressive agents.
The Surgical clinics of North America 1994;74(5):1029-54.
1994: T Hamashima; Stanislaw M Stepkowski; S Smith; Barry D Kahan
Induction of transplantation tolerance by a single intrathymic injection of 3M KCl-extracted donor histocompatibility antigens combined with two doses of anti-rat alpha/beta-T cell receptor monoclonal antibodies.
Transplantation 1994;58(1):105-7.
1994: R J Knight; R Kurrle; J McClain; J Racenberg; V Baghdahsarian; Ronald H Kerman; R Lewis; Charles T Van Buren; Barry D Kahan
Clinical evaluation of induction immunosuppression with a murine IgG2b monoclonal antibody (BMA 031) directed toward the human alpha/beta-T cell receptor.
Transplantation 1994;57(11):1581-8.
1994: R J Knight; R Kurrle; Stanislaw M Stepkowski; F Serino; T C Chou; Barry D Kahan
Synergistic immunosuppressive actions of cyclosporine with a mouse anti-rat alpha/beta-T cell receptor monoclonal antibody.
Transplantation 1994;57(11):1544-8.
1994: R M Lewis; R R Verani; C Vo; S M Katz; Charles T Van Buren; Branislav Radovancevic; Ronald H Kerman; O Howard Frazier; Barry D Kahan
Evaluation of chronic renal disease in heart transplant recipients: importance of pretransplantation native kidney histologic evaluation.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 1994;13(3):376-80.
1994: Ronald H Kerman; Pam Kimball; S Scheinen; Branislav Radovancevic; Charles T Van Buren; Barry D Kahan; O H Frazier
The relationship among donor-recipient HLA mismatches, rejection, and death from coronary artery disease in cardiac transplant recipients.
Transplantation 1994;57(6):884-8.
1994: Kimberly L Napoli; Barry D Kahan
Sample clean-up and high-performance liquid chromatographic techniques for measurement of whole blood rapamycin concentrations.
Journal of chromatography. B, Biomedical applications 1994;654(1):111-20.
1994: Stephen M Katz; Pam Kimball; Claire F Ozaki; H Monsour; James Clark; D Cavazos; Barry D Kahan; R Patrick Wood; Ronald H Kerman
Positive pretransplant crossmatches predict early graft loss in liver allograft recipients.
Transplantation 1994;57(4):616-20.
1994: Barry D Kahan
New immunosuppressive drugs--pharmacologic approaches to alter immunoregulation.
Therapeutic immunology 1994;1(1):33-44.
1994: B J Browne; Barry D Kahan
Transplantation 1994: the year in review.
Clinical transplants 1994;():317-40.
1993: Ronald H Kerman; Pam Kimball; A Lindholm; Charles T Van Buren; Stephen M Katz; R M Lewis; J McClain; J Podbielski; J Williams; Barry D Kahan
Influence of HLA matching on rejections and short- and long-term primary cadaveric allograft survival.
Transplantation 1993;56(5):1242-7.
1993: Mariano Ferraresso; Barry D Kahan
New immunosuppressive agents for pediatric transplantation.
Pediatric nephrology (Berlin, Germany) 1993;7(5):567-73.
1993: Min Wang; Y Tu; Stanislaw M Stepkowski; Barry D Kahan
Effect of cyclosporine alone or in combination with rapamycin and brequinar on survival of hamster heart xenograft in rats.
Transplantation proceedings 1993;25(5):2876-7.
1993: Stanislaw M Stepkowski; R Ghobrial; B Wang; Y Ito; S Goto; T Hamashima; Barry D Kahan
Donor-soluble histocompatibility antigen selectively potentiates suppressor elements while decreasing the frequency of alloantigen-specific T cytotoxic cells.
Transplantation proceedings 1993;25(5):2875.
1993: Mariano Ferraresso; Paolo Rigotti; Stanislaw M Stepkowski; T C Chou; Barry D Kahan
Immunosuppressive effects of defibrotide.
Transplantation 1993;56(4):928-33.
1993: A Lindholm; Barry D Kahan
Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation.
Clinical pharmacology and therapeutics 1993;54(2):205-18.
1993: Barry D Kahan
Optimization of cyclosporine therapy.
Transplantation proceedings 1993;25(4 Suppl 3):5-9.
1993: Ronald H Kerman; Pam Kimball; A Lindholm; Charles T Van Buren; Stephen M Katz; R M Lewis; J Podbielski; J Williams; Barry D Kahan
Immune risk factors: impact on the incidence and diagnosis of rejection.
Transplantation proceedings 1993;25(4 Suppl 3):23-5.
1993: R M Lewis; J Podbielski; M Munsell; Stephen Katz; Charles T Van Buren; Ronald H Kerman; Barry D Kahan
Optimization and long-term evaluation of renal function in sandimmune-treated renal allograft recipients.
Transplantation proceedings 1993;25(4 Suppl 3):10-2.
1993: Barry D Kahan
Timeline of immunosuppression.
Transplantation proceedings 1993;25(4 Suppl 3):1-4.
1993: Stanislaw M Stepkowski; Barry D Kahan
Synergistic activity of the triple combination: cyclosporine, rapamycin, and brequinar.
Transplantation proceedings 1993;25(3 Suppl 2):29-31.
1993: J Grevel; B K Post; Barry D Kahan
Michaelis-Menten kinetics determine cyclosporine steady-state concentrations: a population analysis in kidney transplant patients.
Clinical pharmacology and therapeutics 1993;53(6):651-60.
1993: A Lindholm; M Welsh; L Rutzky; Barry D Kahan
The adverse impact of high cyclosporine. Clearance rates on the incidences of acute rejection and graft loss.
Transplantation 1993;55(5):985-93.
1993: L J Dumble; S Gibbons; Neelam Tejpal; T C Chou; N G Redgrave; M J Boyle; Barry D Kahan
15 AU81, a prostacyclin analog, potentiates immunosuppression and mitigates renal injury due to cyclosporine.
Transplantation 1993;55(5):1124-8.
1993: R Lewis; J Podbielski; S Sprayberry; M Munsell; Stephen Katz; M Rubin; Pam Kimball; Charles T Van Buren; Ronald H Kerman; Barry D Kahan
Stability of renal allograft glomerular filtration rate associated with long-term use of cyclosporine A.
Transplantation 1993;55(5):1014-7.
1993: Barry D Kahan; Neelam Tejpal; S Gibbons-Stubbers; Y Tu; Min Wang; Stanislaw M Stepkowski; T C Chou
The synergistic interactions in vitro and in vivo of brequinar sodium with cyclosporine or rapamycin alone and in triple combination.
Transplantation 1993;55(4):894-900.
1993: Mariano Ferraresso; R Ghobrial; Stanislaw M Stepkowski; Barry D Kahan
The mechanism of unresponsiveness to allografts induced by rapamycin and rapamycin/cyclosporine treatment in rats.
Transplantation 1993;55(4):888-94.
1993: Mariano Ferraresso; Mou-Er Wang; Stanislaw M Stepkowski; Barry D Kahan
Rescue therapy with rapamycin blocks an ongoing process of heart allograft rejection.
Transplantation proceedings 1993;25(1 Pt 1):729.
1993: Pam Kimball; Ronald H Kerman; J Williams; Barry D Kahan
Cyclosporine and rapamycin block protein kinase C-mediated induction of the activation signal, activator of DNA replication, in cell-free assay.
Transplantation proceedings 1993;25(1 Pt 1):518-9.
1993: Barry D Kahan
Cyclosporine: the base for immunosuppressive therapy--present and future.
Transplantation proceedings 1993;25(1 Pt 1):508-10.
1992: H Komichi; S Smith; Barry D Kahan
Immunotherapy with a tumor-infiltrating lymphocyte clone, soluble antigen, and cyclophosphamide.
Archives of surgery (Chicago, Ill. : 1960) 1992;127(12):1417-23.
1992: Mou-Er Wang; Stanislaw M Stepkowski; Mariano Ferraresso; Barry D Kahan
Evidence that rapamycin rescue therapy delays rejection of major (MHC) plus minor (non-MHC) histoincompatible heart allografts in rats.
Transplantation 1992;54(4):704-9.
1992: A Lindholm; M Welsh; C Alton; Barry D Kahan
Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability.
Clinical pharmacology and therapeutics 1992;52(4):359-71.
1992: A Lindholm; Kimberly L Napoli; L Rutzky; Barry D Kahan
Specific monoclonal radioimmunoassay and fluorescence polarization immunoassay for trough concentration and area-under-the-curve monitoring of cyclosporine in renal transplantation.
Therapeutic drug monitoring 1992;14(4):292-300.
1992: Barry D Kahan; S Gibbons-Stubber; Neelam Tejpal; T C Chou
Prospects for synergistic immunosuppressive drug therapy in the coming decade.
Transplantation proceedings 1992;24(4):1263-5.
1992: Barry D Kahan
Cyclosporin A, FK506, rapamycin: the use of a quantitative analytic tool to discriminate immunosuppressive drug interactions.
Journal of the American Society of Nephrology : JASN 1992;2(12 Suppl):S222-7.
1992: S Goto; Stanislaw M Stepkowski; Barry D Kahan
Benefit of multiple over single doses of 3M KCL-extracted histocompatibility antigen in the potentiating cyclosporine-induced prolongation of rat cardiac allograft survival.
Transplantation 1992;53(3):705-7.
1992: Barry D Kahan; M Welsh; L Rutzky; R Lewis; R Knight; Stephen Katz; Kimberly L Napoli; J Grevel; Charles T Van Buren
The ability of pretransplant test-dose pharmacokinetic profiles to reduce early adverse events after renal transplantation.
Transplantation 1992;53(2):345-51.
1992: Stanislaw M Stepkowski; H F Chen; Mou-Er Wang; P Daloze; Barry D Kahan
Inhibition of host-versus-graft and graft-versus-host responses after small bowel transplantation in rats by rapamycin.
Transplantation 1992;53(2):258-64.
1992: Ronald H Kerman; Pam Kimball; Charles T Van Buren; R M Lewis; D Cavazos; A Heydari; Barry D Kahan
Influence of race on crossmatch outcome and recipient eligibility for transplantation.
Transplantation 1992;53(1):64-7.
1992: R J Knight; A Vathsala; Linda Schoenberg; S Camel; R B Weinberg; R A Goldstein; R M Lewis; Charles T Van Buren; Barry D Kahan
Treatment of hyperlipidemia in renal transplant patients with gemfibrozil and dietary modification.
Transplantation 1992;53(1):224-5.
1992: Barry D Kahan
New immunosuppressive drugs: needs in and applications to pediatric transplantation.
European journal of pediatrics 1992;151 Suppl 1():S9-12.
1991: Stanislaw M Stepkowski; Barry D Kahan
Rapamycin and cyclosporine synergistically prolong heart and kidney allograft survival.
Transplantation proceedings 1991;23(6):3262-4.
1991: J Grevel; Barry D Kahan
Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy.
Clinical chemistry 1991;37(11):1905-8.
1991: S Miyagawa; Stanislaw M Stepkowski; J G Lawen; L P Rutzky; Barry D Kahan
In vitro correlates of in vivo therapy with cyclosporine to immunosuppress rejection of heterotopic rat cardiac allografts across strong (RT-1) plus weak (non-RT-1) histocompatibility differences.
Transplantation 1991;52(5):851-7.
1991: K Delhey; R Lewis; J Dunn; J Berry; R Gray; Charles T Van Buren; Barry D Kahan
Absence of tumor transmission from a cadaveric renal donor with malignant astrocytoma and a ventriculoperitoneal shunt--two-year recipient follow-up and review of the literature.
Transplantation 1991;52(4):737-8.
1991: Kimberly L Napoli; Barry D Kahan
Considerations for monitoring cyclosporine in transplant recipients.
Clinics in laboratory medicine 1991;11(3):671-91.
1991: Barry D Kahan; J Y Chang; S N Sehgal
Preclinical evaluation of a new potent immunosuppressive agent, rapamycin.
Transplantation 1991;52(2):185-91.
1991: A Vathsala; S Goto; N Yoshimura; Stanislaw M Stepkowski; T C Chou; Barry D Kahan
The immunosuppressive antagonism of low doses of FK506 and cyclosporine.
Transplantation 1991;52(1):121-8.
1991: F Citterio; Barry D Kahan
Cyclosporine's dual mechanism of action in inhibiting generation of the cytoplasmic activation signal and the nuclear response thereto.
Transplantation 1991;51(6):1248-57.
1991: J Grevel; Barry D Kahan
Area under the curve monitoring of cyclosporine therapy: the early posttransplant period.
Therapeutic drug monitoring 1991;13(2):89-95.
1991: J Grevel; Kimberly L Napoli; M S Welsh; N E Atkinson; Barry D Kahan
Prediction of acute graft rejection in renal transplantation: the utility of cyclosporine blood concentrations.
Pharmaceutical research 1991;8(2):278-81.
1991: Pam Kimball; Ronald H Kerman; Barry D Kahan
Failure of prolyl-peptidyl isomerase to mediate cyclosporine suppression of intracellular activation signal generation.
Transplantation 1991;51(2):509-13.
1991: R J Knight; Ronald H Kerman; M Welsh; D Golden; Linda Schoenberg; Charles T Van Buren; R M Lewis; Barry D Kahan
Chronic rejection in primary renal allograft recipients under cyclosporine-prednisone immunosuppressive therapy.
Transplantation 1991;51(2):355-9.
1991: Ronald H Kerman; Pam Kimball; Charles T Van Buren; R M Lewis; V DeVera; V Baghdahsarian; A Heydari; Barry D Kahan
AHG and DTE/AHG procedure identification of crossmatch-appropriate donor-recipient pairings that result in improved graft survival.
Transplantation 1991;51(2):316-20.
1991: Ronald H Kerman; Pam Kimball; Charles T Van Buren; R M Lewis; V DeVera; V Baghdahsarian; A Heydari; Barry D Kahan
Improved renal allograft survival for AHG and DTE/AHG crossmatch-negative recipients.
Transplantation proceedings 1991;23(1 Pt 1):400-2.
1991: Ronald H Kerman; Pam Kimball; Charles T Van Buren; R M Lewis; Barry D Kahan
Stronger immune responsiveness of blacks vs whites may account for renal allograft survival differences.
Transplantation proceedings 1991;23(1 Pt 1):380-2.
1991: Pam Kimball; Ronald H Kerman; Barry D Kahan
Cyclosporine suppression of intracellular activation signal generation is not mediated by prolyl-peptidyl isomerase.
Transplantation proceedings 1991;23(1 Pt 1):323-4.
1991: Stanislaw M Stepkowski; S Goto; J Wiggins; J Christopher; Barry D Kahan
Contribution of CD4+ cells to allorejection across a class I major histocompatibility complex barrier in congeneic rats.
Transplantation proceedings 1991;23(1 Pt 1):172-3.
1991: Pam Kimball; Ronald H Kerman; Barry D Kahan
Rapamycin and cyclosporine produce synergistic but nonidentical mechanisms of immunosuppression.
Transplantation proceedings 1991;23(1 Pt 2):1027-8.
1991: Pam Kimball; Ronald H Kerman; Barry D Kahan
Production of synergistic but nonidentical mechanisms of immunosuppression by rapamycin and cyclosporine.
Transplantation 1991;51(2):486-90.
1991: Stephen M Katz; Ronald H Kerman; D Golden; J Grevel; S Camel; R M Lewis; Charles T Van Buren; Barry D Kahan
Preemptive transplantation--an analysis of benefits and hazards in 85 cases.
Transplantation 1991;51(2):351-5.
1991: Ronald H Kerman; Pam Kimball; Charles T Van Buren; R M Lewis; Barry D Kahan
Possible contribution of pretransplant immune responder status to renal allograft survival differences of black versus white recipients.
Transplantation 1991;51(2):338-42.
1991: Barry D Kahan; S Gibbons; Neelam Tejpal; T C Chou; Stanislaw M Stepkowski
Synergistic effect of the rapamycin-cyclosporine combination: median effect analysis of in vitro immune performances by human T lymphocytes in PHA, CD3, and MLR proliferative and cytotoxicity assays.
Transplantation proceedings 1991;23(1 Pt 2):1090-1.
1991: S Goto; Stanislaw M Stepkowski; Barry D Kahan
Effect of FK 506 and cyclosporine on heart allograft survival in rats.
Transplantation proceedings 1991;23(1 Pt 1):529-30.
1991: S Miyagawa; Stanislaw M Stepkowski; Barry D Kahan
Mechanism of unresponsiveness in rats induced by a short course of FK 506 or CyA.
Transplantation proceedings 1991;23(1 Pt 1):334-5.
1991: Barry D Kahan; S Gibbons; Neelam Tejpal; Stanislaw M Stepkowski; T C Chou
Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro.
Transplantation 1991;51(1):232-9.
1991: Stanislaw M Stepkowski; H Chen; P Daloze; Barry D Kahan
Rapamycin, a potent immunosuppressive drug for vascularized heart, kidney, and small bowel transplantation in the rat.
Transplantation 1991;51(1):22-6.
1991: N Yoshimura; T Oka; Barry D Kahan
Sequential determinations of serum interleukin 6 levels as an immunodiagnostic tool to differentiate rejection from nephrotoxicity in renal allograft recipients.
Transplantation 1991;51(1):172-6.
1991: Barry D Kahan
Transplantation timeline. Mankind's three millennia--one maverick's three decades in the struggle against biochemical individuality.
Transplantation 1991;51(1):1-21.
1990: Barry D Kahan; L M Shaw; D Holt; J Grevel; A Johnston
Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine.
Clinical chemistry 1990;36(8 Pt 1):1510-6.
1990: F Citterio; A E Chiocca; Barry D Kahan
Nuclear effects of cyclosporine.
Transplantation proceedings 1990;22(4):1742-3.
1990: J Grevel; Kimberly L Napoli; Barry D Kahan
Covariables in cyclosporine immunosuppression.
Transplantation proceedings 1990;22(3):1113-5.
1990: Barry D Kahan
Summary on therapeutic drug monitoring for renal transplantation.
Transplantation proceedings 1990;22(3):1348-51.
1990: J Grevel; Kimberly L Napoli; Barry D Kahan
Steady-state concentrations of cyclosporine for therapeutic monitoring.
Transplantation proceedings 1990;22(3):1339-42.
1990: Barry D Kahan; Kimberly L Napoli; M Welsh; J Grevel; L P Rutzky
Comparison of the utility of 3H-based specific monoclonal antibody assay on whole blood samples with the fluorescence polarization nonspecific immunoassay on serum samples for diagnosis of adverse events in renal transplant patients.
Transplantation proceedings 1990;22(3):1274-9.
1990: Kimberly L Napoli; Barry D Kahan
Nonselective measurement of cyclosporine for therapeutic drug monitoring by fluorescence polarization immunoassay with a sheep polyclonal antibody: II. Evaluation of the whole blood methodology and comparison with an 3H tracer-mediated radioimmunoassay with a sheep polyclonal antibody.
Transplantation proceedings 1990;22(3):1181-5.
1990: Kimberly L Napoli; Barry D Kahan
Nonselective measurement of cyclosporine for therapeutic drug monitoring by fluorescence polarization immunoassay with a rabbit polyclonal antibody: I. Evaluation of the serum methodology and comparison with a sheep polyclonal antibody in an 3H-tracer mediated radioimmunoassay.
Transplantation proceedings 1990;22(3):1175-80.
1990: Barry D Kahan
The phoenix: symbol of rebirth and the eternal return.
Transplantation proceedings 1990;22(3):1097-103.
1990: L S Florence; G L Jiang; K K Ang; Stanislaw M Stepkowski; Barry D Kahan
In vitro analysis of T cell-mediated cytotoxicity displayed by rat heart allograft recipients rendered unresponsive by total-lymphoid irradiation and extracted donor antigen.
Transplantation 1990;49(2):436-44.
1990: P T Roughneen; A D Kulkarni; D A Thompson; S Kumar; Charles T Van Buren; Barry D Kahan; B J Rowlands
Temporal T cell suppression and impaired host responsiveness to nonvascularized neonatal cardiac allografts in experimental hepatic failure.
Transplantation proceedings 1990;22(1):291-3.
1990: J Dunn; D Golden; Charles T Van Buren; R M Lewis; J Lawen; Barry D Kahan
Causes of graft loss beyond two years in the cyclosporine era.
Transplantation 1990;49(2):349-53.
1990: T Ito; Stanislaw M Stepkowski; Barry D Kahan
Soluble antigen and cyclosporine-induced specific unresponsiveness in rats. Frequency of alloantigen-specific T cytotoxic cells in normal, sensitized, and unresponsive rats.
Transplantation 1990;49(2):422-8.
1990: A Vathsala; T C Chou; Barry D Kahan
Analysis of the interactions of immunosuppressive drugs with cyclosporine in inhibiting DNA proliferation.
Transplantation 1990;49(2):463-72.
1990: J Grevel; Kimberly L Napoli; S Gibbons; Barry D Kahan
Area-under-the-curve monitoring of cyclosporine therapy: performance of different assay methods and their target concentrations.
Therapeutic drug monitoring 1990;12(1):8-15.
1990: Ronald H Kerman; Charles T Van Buren; R M Lewis; V DeVera; V Baghdahsarian; K Gerolami; Barry D Kahan
Improved graft survival for flow cytometry and antihuman globulin crossmatch-negative retransplant recipients.
Transplantation 1990;49(1):52-6.
1990: A Vathsala; R Verani; Linda Schoenberg; R M Lewis; Charles T Van Buren; Ronald H Kerman; Barry D Kahan
Proteinuria in cyclosporine-treated renal transplant recipients.
Transplantation 1990;49(1):35-41.
1990: J Dunn; J Grevel; Kimberly L Napoli; R M Lewis; Charles T Van Buren; Barry D Kahan
The impact of steady-state cyclosporine concentrations on renal allograft outcome.
Transplantation 1990;49(1):30-4.
1990: Pam Kimball; Ronald H Kerman; Barry D Kahan
Sensitivity of intracellular signals responsible for cell cycle progression to cyclosporine.
Transplantation 1990;49(1):186-91.
1989: J Dunn; A Vathsala; D Golden; Ronald H Kerman; J Lawen; Charles T Van Buren; R Lewis; Barry D Kahan
Impact of race on the outcome of renal transplantation under cyclosporine-prednisone.
Transplantation proceedings 1989;21(6):3946-8.
1989: A Vathsala; R B Weinberg; Linda Schoenberg; J Grevel; J Dunn; R A Goldstein; Charles T Van Buren; R M Lewis; Barry D Kahan
Lipid abnormalities in renal transplant recipients treated with cyclosporine.
Transplantation proceedings 1989;21(4):3670-3.
1989: A Vathsala; R B Weinberg; Linda Schoenberg; J Grevel; R A Goldstein; Charles T Van Buren; R M Lewis; Barry D Kahan
Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients.
Transplantation 1989;48(1):37-43.
1989: Barry D Kahan
Ganesha: the primeval Hindu xenograft.
Transplantation proceedings 1989;21(3 Suppl 1):1-8.
1989: Barry D Kahan
Pharmacokinetics and pharmacodynamics of cyclosporine.
Transplantation proceedings 1989;21(3 Suppl 1):9-15.
1989: Barry D Kahan
Case presentations in renal transplantation.
Transplantation proceedings 1989;21(3 Suppl 1):70-96.
1989: Barry D Kahan
Clinical problems in cyclosporine dosing with reference to clinical pharmacology: case histories and discussion.
Transplantation proceedings 1989;21(3 Suppl 1):16-40.
1989: Barry D Kahan
The impact of cyclosporine on the practice of renal transplantation.
Transplantation proceedings 1989;21(3 Suppl 1):63-9.
1989: S Goto; Stanislaw M Stepkowski; Barry D Kahan
Multiple injections of KCl-extracted donor-antigen in combination with a short course of cyclosporine therapy induces prolonged heart allograft survival in rats.
Transplantation proceedings 1989;21(2):3300-2.
1989: J Grevel; Paolo Rigotti; F Citterio; M Plebani; Barry D Kahan
The effect of end-to-side portacaval shunt on cyclosporine pharmacokinetics in rats.
Pharmaceutical research 1989;6(3):255-7.
1989: J Grevel; K L Reynolds; L P Rutzky; Barry D Kahan
Influence of demographic factors on cyclosporine pharmacokinetics in adult uremic patients.
Journal of clinical pharmacology 1989;29(3):261-6.
1989: F Citterio; Barry D Kahan
Specificity of the nuclear effect of cyclosporine on the immune cells.
Transplantation proceedings 1989;21(1 Pt 1):842-3.
1989: R M Lewis; Charles T Van Buren; MP Macris; O Howard Frazier; R P Janney; J McAndrew; Ronald H Kerman; Barry D Kahan
Evolution of renal function in cardiac vs. renal allograft recipients receiving long-term cyclosporine A (CsA) immunosuppressive therapy.
Transplantation proceedings 1989;21(1 Pt 2):1523-4.
1989: F Citterio; Barry D Kahan
Effects of cyclosporin on nuclear function of transplant recipient lymphocytes.
Transplantation proceedings 1989;21(1 Pt 2):1465-6.
1989: A Y Smith; F Citterio; M Welsh; Ronald H Kerman; Barry D Kahan
Interleukin-2 receptor as an immunodiagnostic tool to differentiate rejection from nephrotoxicity.
Transplantation proceedings 1989;21(1 Pt 2):1462-4.
1989: T Ito; Stanislaw M Stepkowski; Barry D Kahan
Decreased frequency of alloantigen-specific T cells following immunosuppression with extracted donor histocompatibility antigen and a brief course of cyclosporine.
Transplantation proceedings 1989;21(1 Pt 1):248-51.
1989: Stanislaw M Stepkowski; S Goto; K Reynolds; T Ito; Barry D Kahan
Induction of unresponsiveness after local low-dose cyclosporine administration.
Transplantation proceedings 1989;21(1 Pt 1):1120-2.
1989: R M Lewis; R P Janney; D L Golden; N B Kerr; Charles T Van Buren; Ronald H Kerman; Barry D Kahan
Stability of renal allograft function associated with long-term cyclosporine immunosuppressive therapy--five year follow-up.
Transplantation 1989;47(2):266-72.
1989: Barry D Kahan; Ronald H Kerman; Charles T Van Buren; S M Flechner; D L Golden; R M Lewis
Clinical outcome in 36 patients after at least one and up to 5 years of steroid withdrawal based upon specific mixed lymphocyte reaction hyporesponsiveness toward the living related donor.
Transplantation proceedings 1989;21(1 Pt 2):1579-80.
1989: F Citterio; Barry D Kahan
The inhibitory effect of cyclosporine on the nuclear proliferative response to a variety of T cell activators.
Transplantation 1989;47(2):334-8.
1989: J Grevel; M S Welsh; Barry D Kahan
Cyclosporine monitoring in renal transplantation: area under the curve monitoring is superior to trough-level monitoring.
Therapeutic drug monitoring 1989;11(3):246-8.
1989: Stanislaw M Stepkowski; S Goto; T Ito; K Reynolds; R Didlake; E K Kim; Barry D Kahan
Prolongation of heterotopic heart allograft survival by local delivery of continuous low-dose cyclosporine therapy.
Transplantation 1989;47(1):17-23.
1989: L S Florence; T Ito; K K Ang; G L Jiang; C S Wong; S Goto; R Didlake; E K Kim; Stanislaw M Stepkowski; Barry D Kahan
The synergistic effect of total-lymphoid irradiation with extracted donor alloantigen in inducing transplantation unresponsiveness.
Transplantation 1989;47(1):156-62.
1989: T Roesel; S J LeGrue; J Liehr; Barry D Kahan
Isolation and in vitro characterization of a novel immunosuppressive cyclosporine metabolite.
Transplantation 1989;47(1):149-56.
1988: R Didlake; E K Kim; Barry D Kahan
Ability of 3M KC1-extracted histocompatibility antigen to potentiate the immunosuppressive effect of cyclosporine to prolong the survival of heterotopic rat cardiac allografts.
Transplantation 1988;46(5):743-7.
1988: Barry D Kahan; J Grevel
Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy.
Transplantation 1988;46(5):631-44.
1988: R H Didlake; K Dreyfus; Ronald H Kerman; Charles T Van Buren; Barry D Kahan
Patient noncompliance: a major cause of late graft failure in cyclosporine-treated renal transplants.
Transplantation proceedings 1988;20(3 Suppl 3):63-9.
1988: R M Lewis; R P Janney; Charles T Van Buren; Ronald H Kerman; J Herson; N A Kerr; D A Golden; Barry D Kahan
A retrospective analysis of long-term renal allograft function associated with cyclosporine-prednisone immunosuppressive therapy.
Transplantation proceedings 1988;20(3 Suppl 3):534-9.
1988: Barry D Kahan
Renal transplantation.
Transplantation proceedings 1988;20(3 Suppl 3):297-310.
1988: S B Conley; Ronald J Portman; J M Lemire; Charles T Van Buren; R Lewis; Barry D Kahan
Five years' experience with cyclosporine in children.
Transplantation proceedings 1988;20(3 Suppl 3):280-4.
1988: Ronald H Kerman; Charles T Van Buren; R M Lewis; Barry D Kahan
Impact of blood transfusions and HLA on cyclosporine-treated renal transplant recipients.
Transplantation proceedings 1988;20(3 Suppl 3):264-9.
1988: A Y Smith; Ronald H Kerman; Charles T Van Buren; R M Lewis; Barry D Kahan
Pediatric cadaveric kidneys in recipients treated with cyclosporine.
Transplantation proceedings 1988;20(3 Suppl 3):215-21.
1988: A Y Smith; Charles T Van Buren; R M Lewis; Ronald H Kerman; M Welsh; Barry D Kahan
The outcome of repeat cadaveric kidney transplants in recipients managed with cyclosporine.
Transplantation proceedings 1988;20(3 Suppl 3):180-93.
1988: T Ito; Stanislaw M Stepkowski; Barry D Kahan
Frequency of T cytotoxic cells after perioperative treatment with extracted antigen and cyclosporine in rat cardiac transplantation.
Transplantation proceedings 1988;20(3 Suppl 3):1045-52.
1988: Barry D Kahan; R Didlake; E E Kim; N Yoshimura; E Kondo; Stanislaw M Stepkowski
Important role of cyclosporine for the induction of immunologic tolerance in adult hosts.
Transplantation proceedings 1988;20(3 Suppl 3):23-35.
1988: R H Didlake; E K Kim; Barry D Kahan
Impact of a combined regimen of cyclosporine and 3M KCl extracted histocompatibility antigen on heterotopic rat cardiac allograft survival.
Transplantation proceedings 1988;20(3 Suppl 3):1034-7.
1988: F Citterio; Barry D Kahan
Effects of cyclosporine on nuclear function.
Transplantation proceedings 1988;20(2 Suppl 2):75-9.
1988: K L Reynolds; J Grevel; S Y Gibbons; M S Welsh; L P Rutzky; Barry D Kahan
Cyclosporine pharmacokinetics in uremic patients: influence of different assay methods.
Transplantation proceedings 1988;20(2 Suppl 2):462-5.
1988: S Gibbons; J Grevel; K Reynolds; M Ried; L P Rutzky; Barry D Kahan
Comparison and correlation of assays for monitoring cyclosporine drug levels in renal transplant recipients.
Transplantation proceedings 1988;20(2 Suppl 2):339-44.
1988: Barry D Kahan
Pien Ch'iao, the legendary exchange of hearts, traditional Chinese medicine, and the modern era of cyclosporine.
Transplantation proceedings 1988;20(2 Suppl 2):2-12.
1988: R H Didlake; E K Kim; J Grevel; L Jarolimek; Barry D Kahan
Cyclosporine pharmacokinetics and pharmacodynamics after oral administration in the rat.
Transplantation proceedings 1988;20(2 Suppl 2):692-5.
1988: Barry D Kahan; R Didlake; E E Kim; N Yoshimura; E Kondo; Stanislaw M Stepkowski
Important role of cyclosporine for the induction of immunologic tolerance in adult hosts.
Transplantation proceedings 1988;20(2 Suppl 2):438-50.
1988: K Kakizaki; G Basadonna; Barry D Kahan; R Merrell
Cyclosporine absorption in apancreatic dogs.
American journal of surgery 1988;155(3):467-9.
1988: A Y Smith; Charles T Van Buren; R M Lewis; Ronald H Kerman; Barry D Kahan
Short-term and long-term function of cadaveric kidneys from pediatric donors in recipients treated with cyclosporine.
Transplantation 1988;45(2):360-7.
1988: Ronald H Kerman; Charles T Van Buren; R M Lewis; O H Frazier; D Cooley; Barry D Kahan
The impact of HLA A, B, and DR blood transfusions and immune responder status on cardiac allograft recipients treated with cyclosporine.
Transplantation 1988;45(2):333-7.
1988: R M Lewis; P C Johnson; D Golden; Charles T Van Buren; Ronald H Kerman; Barry D Kahan
The adverse impact of cytomegalovirus infection on clinical outcome in cyclosporine-prednisone treated renal allograft recipients.
Transplantation 1988;45(2):353-9.
1988: Ronald H Kerman; Charles T Van Buren; R M Lewis; Barry D Kahan
Successful transplantation of 100 untransfused cyclosporine-treated primary recipients of cadaveric renal allografts.
Transplantation 1988;45(1):37-40.
1988: R Colon; O Howard Frazier; Barry D Kahan; B Radovancevic; J M Duncan; M I Lorber; C T Van Buren
Complications in cardiac transplant patients requiring general surgery.
Surgery 1988;103(1):32-8.
1988: K Naito; N R Pellis; Barry D Kahan
Active specific immunotherapy with extracted tumor-specific transplantation antigen, cyclophosphamide, and adoptive transfer of tumor-specific cytotoxic T-cell clones.
Cellular immunology 1988;111(1):216-34.
1988: K Naito; N R Pellis; Barry D Kahan
Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
Cancer research 1988;48(1):101-8.
1988: Ronald H Kerman; Charles T Van Buren; R M Lewis; Barry D Kahan
Blood transfusion experience for cyclosporine/prednisone-treated renal allograft recipients at the University of Texas Medical School at Houston.
Clinical transplants 1988;():167-70.
1988: R H Didlake; E K Kim; K Sheehan; R D Schreiber; Barry D Kahan
Effect of combined anti-gamma interferon antibody and cyclosporine therapy on cardiac allograft survival in the rat.
Transplantation 1988;45(1):222-3.
1988: P C Johnson; R M Lewis; D L Golden; P E Oefinger; Charles T Van Buren; Ronald H Kerman; Barry D Kahan
The impact of cytomegalovirus infection on seronegative recipients of seropositive donor kidneys versus seropositive recipients treated with cyclosporine-prednisone immunosuppression.
Transplantation 1988;45(1):116-21.
1987: Barry D Kahan; S Conley; Ronald J Portman; R Lemaire; C Wideman; S Flechner; Charles T Van Buren
Parent-to-child transplantation with cyclosporine immunosuppression.
The Journal of pediatrics 1987;111(6 Pt 2):1012-6.
1987: M V Jarowenko; S M Flechner; Charles T Van Buren; M I Lorber; Barry D Kahan
Influence of cyclosporine on posttransplant blood pressure response.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1987;10(2):98-103.
1987: Barry D Kahan
Cyclosporin as an adjunct to the induction of specific unresponsiveness.
Annales de l'Institut Pasteur. Immunology 1987;138(4):618-21.
1987: P T Roughneen; R Didlake; S C Kumar; Barry D Kahan; B J Rowlands
The protective effect of hepatic dysfunction on vascularized allograft survival.
The Journal of surgical research 1987;42(5):447-53.
1987: K Kakizaki; R Didlake; G Basadonna; Barry D Kahan; R C Merrell
Donor-specific antigen and cyclosporine in rat islet allografts.
The Journal of surgical research 1987;42(5):494-7.
1987: P T Roughneen; R Didlake; S C Kumar; Barry D Kahan; B J Rowlands
Enhancement of heterotopic cardiac allograft survival by experimental biliary ligation.
Transplantation 1987;43(3):437-8.
1987: M I Lorber; Charles T Van Buren; S M Flechner; C Williams; Barry D Kahan
Hepatobiliary complications of cyclosporine therapy following renal transplantation.
Transplantation proceedings 1987;19(1 Pt 2):1808-10.
1987: M I Lorber; Charles T Van Buren; S M Flechner; L Cameron; J Leatherwood; W E Walker; R W Smalling; Barry D Kahan
Pretransplant coronary arteriography for diabetic renal transplant recipients.
Transplantation proceedings 1987;19(1 Pt 2):1539-41.
1987: R Didlake; K Kakazaki; N Yoshimura; R Merrell; Barry D Kahan
Effects of a combined antigen-cyclosporine regimen in four transplantation models.
Transplantation proceedings 1987;19(1 Pt 2):1281-3.
1987: T L Burstain; O Howard Frazier; M J Schnee; Ronald H Kerman; M I Lorber; Denton A Cooley; B Radovancevic; R Colon; H McAllister; Barry D Kahan
Predictors of rejection in cyclosporine-treated cardiac allograft recipients.
Transplantation proceedings 1987;19(1 Pt 3):2531-3.
1987: A Y Smith; Charles T Van Buren; R M Lewis; Ronald H Kerman; Barry D Kahan
Factors determining renal transplant outcome at the University of Texas at Houston.
Clinical transplants 1987;():155-66.
1986: M V Jarowenko; Charles T Van Buren; W G Kramer; M I Lorber; S M Flechner; Barry D Kahan
Ranitidine, cimetidine, and the cyclosporine-treated recipient.
Transplantation 1986;42(3):311-2.
1985: Barry D Kahan; R H Kerman; C A Wideman; S M Flechner; M Jarowenko; Charles T Van Buren
Impact of cyclosporine on renal transplant practice at the University of Texas Medical School at Houston.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1985;5(6):288-95.
1985: M V Jarowenko; S M Flechner; C M Sandler; Charles T Van Buren; Barry D Kahan
Salvage of difficult transplant complications by percutaneous techniques.
The Journal of urology 1985;133(5):840-3.
1985: Barry D Kahan; Charles T Van Buren; S M Flechner; M Jarowenko; T Yasumura; A J Rogers; N Yoshimura; S LeGrue; D Drath; R H Kerman
Clinical and experimental studies with cyclosporine in renal transplantation.
Surgery 1985;97(2):125-40.
1984: D Van Buren; C A Wideman; M Ried; S Gibbons; Charles T Van Buren; M Jarowenko; S M Flechner; O H Frazier; D A Cooley; Barry D Kahan
The antagonistic effect of rifampin upon cyclosporine bioavailability.
Transplantation proceedings 1984;16(6):1642-5.
1984: Barry D Kahan; C Wideman; S Gibbons; M Ried; M Jarowenko; S Flechner; Charles T Van Buren
Impact of mode of pretransplant loading with cyclosporine on the incidence of early rejection in haploidentical living related donor renal recipients.
Transplantation proceedings 1984;16(6):1619-23.
1984: Barry D Kahan; C A Wideman; M Reid; S Gibbons; M Jarowenko; S Flechner; Charles T Van Buren
The value of serial serum trough cyclosporine levels in human renal transplantation.
Transplantation proceedings 1984;16(5):1195-9.
1984: Barry D Kahan; C A Wideman; S Flechner; Charles T Van Buren
Anaphylactic reaction to intravenous cyclosporin.
Lancet 1984;1(8367):52.
1983: Barry D Kahan; Charles T Van Buren; M Boileau; M Ried; W D Payne; S Flechner; J Newburger
Cyclosporin A tissue levels in a cadaveric renal allograft recipient.
Transplantation 1983;35(1):96-9.